Application

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected p21 in HUVEC and NIH 3T3 cells.Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected p21 in human cervical cancer tissue sections.Note: Actual optimal working dilutions must be determined by the end user as specimens and experimental conditions may vary.

Anti-p21, clone 5G7 ZooMAb , Cat. No. ZRB1141, is a recombinant rabbit monoclonal antibody that specifically targets p21-Waf1-Cip1 and has been tested for use in Immunocytochemistry, Immunohistochemistry (Paraffin), and Western Blotting.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

His-tagged full-length recombinant human Cyclin-dependent kinase inhibitor 1 (p21).

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose. Normal appearance is a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

300 µg/mL after reconstitution at 25 µL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 5G7 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects p21/Waf1/Cip1 protein.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Cyclin-dependent kinase inhibitor 1 (UniProt: P38936; also known as CDK-interacting protein 1, Melanoma differentiation-associated protein 6, MDA-6, p21) is encoded by the CDKN1A (also known as CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WAF1) gene (Gene ID:1026) in human. p21 belongs to the Cip and Kip family of CDK inhibitors. It binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. It binds tightly to the G1 and S phase kinases, cyclin E/Cdk2, cyclin D/Cdk4, and cyclin A/Cdk2, and effectively inhibits their activity. However, its effects on G2/M kinases is minimal. It binds the cyclin subunit through a conserved Cy1 motif in the N-terminal half and through a weaker and Cy2 motif in the C-terminal half. p21 also inhibits proliferating cell nuclear antigen (PCNA) and binds to and blocks the inactivation of retinoblastoma protein (Rb), which is essential for cell cycle progression. It is an important effector of p53 and is important in the DNA-damage checkpoint. It is expressed in all adult tissues, with 5-fold lower levels observed in the brain. Is cyclin binding site is localized to amino acids 17-24 and CDK binding occurs in the region of 53-58 residues. p21 is shown to suppress tumor growth by promoting cell cycle arrest in response to various stimuli. However, it is often misregulated in various human cancers. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Abbas, T., and Dutta, A (2009). Nat Rev Cancer. 9(6); 400-414).